Cargando…

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities

High‐dose cytarabine (Ara‐C) has been reported with increased treatment‐related mortality, whereas few data are available concerning intermediate‐dose Ara‐C for induction of acute myeloid leukemia (AML) with t(8;21) translocation. We retrospectively analyzed factors impacting complete remission (CR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Biao, Yang, Bin, Ling, Yun, Zhang, Jihong, Hua, Xiaoying, Gu, Weiying, Yan, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897948/ https://www.ncbi.nlm.nih.gov/pubmed/33382538 http://dx.doi.org/10.1002/cam4.3705

Ejemplares similares

Prognostication refinement in NPM1‐mutated acute myeloid leukemia stratified by FLT3‐ITD status with different induction doses of cytarabine
por: Wang, Biao, et al.
Publicado: (2023)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
por: Cao, Jiang, et al.
Publicado: (2016)

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
por: Yang, Lu, et al.
Publicado: (2019)

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
por: Qin, Ya-Zhen, et al.
Publicado: (2018)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

KIT D816突变对伴t(8;21)复发急性髓系白血病预后的影响
Publicado: (2018)

Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
por: Su, Kuan-Wei, et al.
Publicado: (2021)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
por: Ustun, Celalettin, et al.
Publicado: (2018)

High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia
por: Gao, Xiaoning, et al.
Publicado: (2015)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
por: Sandow, Lyndsey, et al.
Publicado: (2023)

The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
por: Chen, Guofeng, et al.
Publicado: (2022)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation
por: Rai, Shinya, et al.
Publicado: (2021)

Single-cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction
por: Xiong, Qian, et al.
Publicado: (2020)

Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Yang, Erna, et al.
Publicado: (2021)

A Novel KIT INDEL Mutation in Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
por: Lee, Jun Hyung, et al.
Publicado: (2016)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia
por: Lopes, Marta, et al.
Publicado: (2018)

Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
por: Pullarkat, Sheeja T., et al.
Publicado: (2009)

A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21)
por: Trivedi, P. J., et al.
Publicado: (2008)

Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Zhou, Lei, et al.
Publicado: (2018)

Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia
por: Yu, Xianjun, et al.
Publicado: (2016)

Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)
por: Lu, Lianghao, et al.
Publicado: (2018)

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)
por: Wilde, Lindsay, et al.
Publicado: (2019)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
por: Tsai, Hui‐Jen, et al.
Publicado: (2021)

Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia
por: Wang, Biao, et al.
Publicado: (2020)

t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming
por: Kellaway, Sophie, et al.
Publicado: (2020)

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V
por: Rai, Shinya, et al.
Publicado: (2020)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
por: Lo, Miao-Chia, et al.
Publicado: (2013)

De novo Leukemic Variant of Mast Cell Leukemia With KIT D816V
por: Bang, Hae In, et al.
Publicado: (2015)

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
por: Hartmann, Luise, et al.
Publicado: (2016)

Modelling t(8;21) acute myeloid leukaemia ‐ What have we learned?
por: Chin, Paulynn Suyin, et al.
Publicado: (2020)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
por: Meng, Guangqiang, et al.
Publicado: (2019)

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)
por: Xu, Nan, et al.
Publicado: (2022)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia
por: Huang, Sai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mrkovs76ga0a7fmkr4t6am6kqg